Interferon-beta antibodies: implications for the treatment of MS

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.

Lancet (London, England)·2026

Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis.

Annals of neurology·2025

Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.

Multiple sclerosis (Houndmills, Basingstoke, England)·2025

Ethnoracial disparities in gray matter atrophy are mediated by structural disconnectivity in multiple sclerosis.

Annals of clinical and translational neurology·2025

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.

The Lancet. Neurology·2024

The history of the European Neurological Society (1986-2014)-10 years later.

European journal of neurology·2024

Prevalence of unruptured intracranial aneurysms according to comorbidities, risk factors, country, and time period: a systematic review and meta-analysis.

The Lancet. Neurology·2026

Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial.

The Lancet. Neurology·2026

Cholinesterase inhibitors in people with dementia with Lewy bodies and cardiac conduction abnormalities.

The Lancet. Neurology·2026

Advances in chronic subdural haematoma management: beyond the burr hole.

The Lancet. Neurology·2026

Antiseizure medication use in pregnancy and the risk of poor fetal growth in the EURAP international registry: a prospective cohort study.

The Lancet. Neurology·2026

Intensive blood pressure lowering after spontaneous intracerebral haemorrhage for secondary stroke prevention (RECAP-ICH): a systematic review and individual participant data meta-analysis.

The Lancet. Neurology·2026

TPST Gene Knock-Out Eliminates Tyrosine Sulfation on a Recombinant Antibody Produced in CHO Cells.

Biotechnology journal·2026

Antibody framework engineering enables augmented cytokine receptor signaling capacities of bispecific single domain antibody-based IL-21 mimetics.

mAbs·2026

Lymphocyte activation gene 3 in autoimmune disease: from molecular mechanisms to clinical applications.

Frontiers in immunology·2026

Sacubitril/Valsartan: Breaking barriers in uterine adhesion and boosting pregnancy outcomes by suppressing inflammation and fibrosis.

Iranian journal of basic medical sciences·2026

Immune-Related Cystitis Following Immune Checkpoint Inhibitor Therapy: A Report of Two Cases.

Case reports in medicine·2026

Acute Thrombotic Occlusion Induced by an Inferior Vena Cava Filter Implanted 13 Years Earlier, Treated with the Indigo System and Filter Retrieval.

Annals of vascular diseases·2026

Related Experiment Videos

Interferon-beta antibodies: implications for the treatment of MS

Related Concept Videos

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.

Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis.

Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.

Ethnoracial disparities in gray matter atrophy are mediated by structural disconnectivity in multiple sclerosis.

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.

The history of the European Neurological Society (1986-2014)-10 years later.

Prevalence of unruptured intracranial aneurysms according to comorbidities, risk factors, country, and time period: a systematic review and meta-analysis.

Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial.

Cholinesterase inhibitors in people with dementia with Lewy bodies and cardiac conduction abnormalities.

Advances in chronic subdural haematoma management: beyond the burr hole.

Antiseizure medication use in pregnancy and the risk of poor fetal growth in the EURAP international registry: a prospective cohort study.

Intensive blood pressure lowering after spontaneous intracerebral haemorrhage for secondary stroke prevention (RECAP-ICH): a systematic review and individual participant data meta-analysis.

TPST Gene Knock-Out Eliminates Tyrosine Sulfation on a Recombinant Antibody Produced in CHO Cells.

Antibody framework engineering enables augmented cytokine receptor signaling capacities of bispecific single domain antibody-based IL-21 mimetics.

Lymphocyte activation gene 3 in autoimmune disease: from molecular mechanisms to clinical applications.

Sacubitril/Valsartan: Breaking barriers in uterine adhesion and boosting pregnancy outcomes by suppressing inflammation and fibrosis.

Immune-Related Cystitis Following Immune Checkpoint Inhibitor Therapy: A Report of Two Cases.

Acute Thrombotic Occlusion Induced by an Inferior Vena Cava Filter Implanted 13 Years Earlier, Treated with the Indigo System and Filter Retrieval.

Related Experiment Videos

Interferon-beta antibodies: implications for the treatment of MS

Related Concept Videos

Related Articles